Breast cancerBrain metastasisLapatinibCapecitabineLapatinib is a new small molecule tyrosine kinase inhibitor. It targets both ErbB1 and ErbB2 (HER2) receptors and directly and reversibly acts on them to inhibit signaling. Since lapatinib has a low molecular weight, it can cross the blood–brain ...
M. et al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. J. Clin. Oncol. 39, ...
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
https://www.breastcancer.org/facts-statistics 3. Breast cancer metastasis to the brain. Moffitt Cancer Center. Accessed September 19, 2024. https://www.moffitt.org/cancers/brain-tumor/brain-metastases/breast/#:~:text=Breast%20...
Monoclonal antibodies, such as trastuzumab, that bind to HER2 proteins can be used along with chemotherapy to treat patients with HER2-overexpressing breast cancer with metastases to organs outside of the breast. In this paper we present a case of HER2-positive breast cancer liver metastasis ...
HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken). 2020;e1274. 10.1002/cnr2.1274. 33. Peters S, Bexelius C, Munk V, et al. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell ...
Insights on Tucatinib Regimens in HER2+ Breast Cancer Treatment O’Brien on the TBCRC049 Trial in HER2+ Breast Cancer Advances in Treating HER2+ Breast Cancer With Brain Metastases The Impact of T-DXd in HER2-Positive Breast Cancer Challenges in Treating Brain Metastasis in HER2-Positive Breast ...
BACKGROUND: Although trastuzumab therapy improves survival in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, 40% of patients develop brain metastasis (BM) even when extracranial disease is under control. We studied whether trastuzumab therapy beyond or ...
trial in HER2-positive patients with brain metastasis (NCT01494662).137The earlier promising results encouraged the researchers to conduct phase III clinical studies of neratinib. A phase III trial (extended adjuvant treatment of breast cancer with neratinib, ExteNET) showed that neratinib significantly...
The development of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ ...